Drug intelligence / Profile preview

MK-4464 + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MK-4464 + pembrolizumab is an investigational combination therapy for advanced or metastatic solid tumors, currently in Phase 1 clinical trials. MK-4464 is an antibody-based trifunctional molecule (TriNKET, developed by Dragonfly Pharmaceuticals) designed for immunotherapy in cancer. It binds to CEACAM5 on cancer cells and to NKG2D and CD16A on NK cells, thereby recruiting immune cells into tumors and directly activating the killing of cancer cells; it also engages cytotoxic T cells. Pembrolizumab is a programmed death-1 (PD-1) immune checkpoint inhibitor that enhances the immune response against cancer by blocking a pathway tumors use to evade immune destruction. Their combination aims to synergistically improve anti-tumor immune responses by both directly activating immune effector cells (via MK-4464) and removing immune suppression (via pembrolizumab)[2][1][3][5].

Brand names: Keytruda (for pembrolizumab)
Other names: MK4464 + pembrolizumab

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)PDCD1 (Programmed cell death protein 1 receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)

Beyond the preview

Go deeper on MK-4464 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-4464 + pembrolizumab.

Explore the full profile